Open-Label Extension of Other SZ1839 (Iressa) Trials

Multi-Centre, Open-Label Extension Trial of Treatment With ZD1839 (Iressa) in Patients Who Have Been Treated in Other ZD1839 Clinical Trials and May Benefit From Continued Monotherapy ZD 1839.

A trial to assess patients who have been treated with Iressa in a previous clinical trial and may benefit from continued treatment with Iressa.

Inclusion Criteria:

• Received treatment in a previous Iressa clinical trial
• Provided Informed Consent to participate in the trial
• 30 days or less since completing the previous Iressa trial.

Exclusion Criteria:

• Radiotherapy completed more than 14 days before starting treatment in this trial
• Incomplete healing from prior surgery
• Withdrawal from previous Iressa trial due to unacceptable toxicity to major organs